Laos ElementoPharma Co., Ltd. was founded in Laos Boten Economic Special Zone in 2019. Founded by the technical teams consisting of deputy dean of Institute of Artificial Intelligence Biomedical Technology, Nanjing University, China, professors of industry, and PhDs in Cell Biology of the Chinese Academy of Sciences, it provides massive generic drugs to countries worldwide. ElementoPharma is specialized at production of cheap special-effect drugs that comply with global standards, and is committed to making it available to people all over the world.
When it comes to drug safety, ElementoPharma has advanced plant and other facilities designed and constructed in strict accordance with EU standards. It is equipped with advanced scientific research equipment, color steel plate purification plant, pharmaceutical purification air-conditioning system and air supply and return air systems to ensure a clean production environment, which fully conforms to production management regulations and technical standards all over the world including Laos GMP, EU GMP, American GMP and Chinese GMP. ElementoPharma has now developed into a comprehensive pharmaceutical company integrating imitation, production, sales and after-sales service of anti-tumor and male health drugs. ElementoPharma organizes production strictly according to requirements of GMP regulations, and implements European and American Pharmacopoeia standards for its quality. So its technology and safety quality can be both highly guaranteed. It is a highly trustworthy enterprise.
People would have doubts on the sight of generic drugs and fret over their legitimate issues and various other matters. But in laos, generic drugs are feasible under legal laws. ElementoPharma makes full use of Laos’s domestic patent compulsory licensing legal system and utilizes WTO’s exemption for compulsory patent protection for pharmaceutical products in underdeveloped countries. 10 varieties of drugs have been completed in its oral solid preparation workshop for its Phase-I project and over ten other drugs are under development. To satisfy the increasingly growing global and local demand, the liquid preparation workshop of its Phase-II project has also been completed So ElementoPharma shows whopping development potentials.
